Skip to main content

Table 3 Prognostic factors by univariate and multivariate analyses for OS, PFS and BMFS

From: Clinical significance of tumor-infiltrating lymphocytes investigated using routine H&E slides in small cell lung cancer

  OS PFS BMFS (in non-BM and non-PCI)
Univariate analyses Multivariate analyses Univariate analyses Multivariate analyses Univariate analyses
P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI)
Gender 0.542 1.226 0.638–2.355     0.754 0.896 0.452–1.776     0.140 0.224 0.031–1.631
Age 0.867 1.002 0.980–1.025     0.525 0.993 0.972–1.015     0.519 0.988 0.954–1.024
sTIL 0.041 0.675 0.463–0.984 0.027 0.648 0.441–0.951 0.020 0.637 0.436–0.931 0.019 0.632 0.430–0.927 0.029 0.477 0.245–0.927
Clinical T stage 0.288 0.896 0.732–1.097     0.293 1.112 0.912–1.355     0.995 0.999 0.726–1.375
Dmax-T 0.227 1.046 0.973–1.125     0.016 1.087 1.016–1.163     0.783 1.017 0.904–1.142
Clinical N stage 0.014 1.355 1.064–1.724     0.012 1.347 1.069–1.699 0.027 1.298 1.030–1.635 0.218 1.292 0.860–1.940
Clinical M stage 0.000 2.153 1.469–3.156 0.025 1.695 1.069–2.688 0.000 2.128 1.436–3.153 0.001 1.960 1.306–2.941 0.572 0.810 0.390–1.683
Clinical TNM stage 0.001 1.901 1.315–2.749     0.000 1.984 1.371–2.869     0.595 0.845 0.455–1.570
Regimen of CT 0.582 0.951 0.794–1.138     0.158 1.121 0.956–1.315     0.519 0.903 0.663–1.230
Cycles of CT 0.007 0.831 0.727–0.950 0.019 0.835 0.718–0.971 0.352 0.939 0.822–1.072     0.229 1.168 0.907–1.503
TRT 0.000 0.294 0.195–0.445     0.000 0.493 0.333–0.730     0.370 1.390 0.676–2.855
Dose of TRT 0.085 1.000 0.999–1.000     0.412 1.000 1.000–1.001     0.421 1.000 1.000–1.001
PCI 0.052 0.408 0.165–1.008     0.029 0.361 0.145–0.900     NA   
Response to CT 0.003 1.736 1.203–2.507     0.004 1.788 1.209–2.647 0.040 1.514 1.018–2.25 0.605 0.797 0.337–1.886
Response to TRT 0.000 1.176 1.115–1.240 0.000 1.123 1.055–1.196 0.000 1.100 1.046–1.157     0.470 0.967 0.883–1.059